First Patients With Macular Degeneration and Stargardt’s Disease Receive Stem Cell Treatment
July 21, 2011
Advanced Cell Technology announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt’s macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were treated Tuesday (July 12) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA’s Jules Stein Eye Institute.
For the complete story please follow this link.
You might also enjoy...
- Progress Made in Treating Stargardt’s and Dry AMD Using Embryonic Stem Cells
- Using Stem Cells to Treat Dry AMD and Stargardt’s Macular Dystrophy
- A Complete List of Current Ophthalmic Stem Cell Trials
- First Clinical Results of Using Embryonic Stem Cells to Treat Eye Disease Published in The Lancet
- ACT Adds Third Clinical Trial Site for Testing Treatment of Dry Macular Degeneration With Embryonic Stem Cells
Jump down to form below to submit your own comments